{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:02Z","timestamp":1786986842746,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clgc.2025.102451","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:46:19Z","timestamp":1759995979000},"page":"102451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4125-603X","authenticated-orcid":false,"given":"Eugene","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9789-3156","authenticated-orcid":false,"given":"Ye","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-3188","authenticated-orcid":false,"given":"Piroz","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Accardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Koeppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Monda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip L.","family":"Palmbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-8659","authenticated-orcid":false,"given":"Irene","family":"Tsung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-8796","authenticated-orcid":false,"given":"Zachery R.","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulka N","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udit","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Else","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-5501","authenticated-orcid":false,"given":"Charles B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2025.102451_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.clgc.2025.102451_bib0002","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.19.01395","article-title":"Cancer susceptibility mutations in patients with urothelial malignancies","volume":"38","author":"Carlo","year":"2020","journal-title":"J Clin"},{"issue":"4","key":"10.1016\/j.clgc.2025.102451_bib0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41436-019-0720-x","article-title":"Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma","volume":"22","author":"Nassar","year":"2020","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102451_bib0004","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.clgc.2025.102451_bib0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc3878","article-title":"Milestones of Lynch syndrome: 1895\u20132015","volume":"15","author":"Lynch","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clgc.2025.102451_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0032-1313781","article-title":"Extracolonic manifestations of Lynch syndrome","volume":"25","author":"Bansidhar","year":"2012","journal-title":"Clin Colon Rectal Surg"},{"issue":"4","key":"10.1016\/j.clgc.2025.102451_bib0007","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/cancers14041000","article-title":"Upper gastrointestinal cancer surveillance in Lynch syndrome","volume":"14","author":"Kumar","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.clgc.2025.102451_bib0008","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.eururo.2012.07.047","article-title":"Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer","volume":"63","author":"Skeldon","year":"2013","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.clgc.2025.102451_bib0009","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/jmg.2010.076992","article-title":"Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers","volume":"47","author":"van der Post","year":"2010","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.clgc.2025.102451_bib0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/modpathol.2016.171","article-title":"Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome","volume":"30","author":"Harper","year":"2017","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102451_bib0011","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euo.2021.11.001","article-title":"Upper tract urothelial carcinoma in the Lynch syndrome tumour spectrum: a comprehensive overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors","volume":"5","author":"Lonati","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102451_bib0012","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12894-022-01141-1","article-title":"The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Urol"},{"issue":"19","key":"10.1016\/j.clgc.2025.102451_bib0013","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1158\/1078-0432.CCR-22-1006","article-title":"Inherited germline cancer susceptibility gene variants in individuals with non\u2013muscle-invasive bladder cancer","volume":"28","author":"Pietzak","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7_suppl","key":"10.1016\/j.clgc.2025.102451_bib0014","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.2019.37.7_suppl.474","article-title":"Germline alterations in urothelial carcinoma (UC) patients with family history of UC","volume":"37","author":"Nassar","year":"2019","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clgc.2025.102451_bib0015","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2012.48.0988","article-title":"Adrenocortical carcinoma is a lynch syndrome-associated cancer","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102451_bib0016","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.gastro.2019.03.047","article-title":"Outcomes of endoscopic surveillance in individuals with genetic predisposition to hereditary diffuse gastric cancer","volume":"157","author":"Jacobs","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clgc.2025.102451_bib0017","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10689-021-00276-8","article-title":"Outcomes of retesting in patients with previously uninformative cancer genetics evaluations","volume":"21","author":"Sanoba","year":"2022","journal-title":"Fam Cancer"},{"key":"10.1016\/j.clgc.2025.102451_bib0018","article-title":"Pathogenic germline mutational landscape in patients with renal cell carcinoma and associated clinicopathologic features","volume":"7","author":"Nguyen","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102451_bib0019","article-title":"Universal point of care testing for Lynch syndrome in patients with upper tract urothelial carcinoma","volume":"199","author":"Mj","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102451_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.774202","article-title":"Identification of germline mutations in upper tract urothelial carcinoma with suspected Lynch syndrome","volume":"12","author":"Guan","year":"2022","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2025.102451_bib0021","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/PAS.0000000000001141","article-title":"Universal Lynch syndrome screening should be performed in all upper tract urothelial carcinomas","volume":"42","author":"Ju","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.clgc.2025.102451_bib0022","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-18-1354","article-title":"The metabolic basis of kidney cancer","volume":"9","author":"Linehan","year":"2019","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.clgc.2025.102451_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.549","article-title":"A familial case of Birt\u2013Hogg\u2013Dub\u00e9 syndrome complicated with various cancers","volume":"8","author":"Goto","year":"2020","journal-title":"Respirol Case Rep"},{"issue":"6","key":"10.1016\/j.clgc.2025.102451_bib0024","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/cncr.34056","article-title":"Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics","volume":"128","author":"Bychkovsky","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2025.102451_bib0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1940-6207.CAPR-23-0395","article-title":"Triple primary cancers: an analysis of genetic and environmental factors","volume":"17","author":"Borja","year":"2024","journal-title":"Cancer Prev Res"},{"issue":"55","key":"10.1016\/j.clgc.2025.102451_bib0026","doi-asserted-by":"crossref","first-page":"30649","DOI":"10.18632\/oncotarget.25769","article-title":"Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers","volume":"9","author":"Chan","year":"2018","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.clgc.2025.102451_bib0027","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1002\/cncr.28915","article-title":"Knowledge of the harms of tobacco use among patients with bladder cancer","volume":"120","author":"Bassett","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102451_bib0028","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eururo.2012.11.039","article-title":"Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy","volume":"64","author":"Rink","year":"2013","journal-title":"Eur Uro"},{"issue":"1","key":"10.1016\/j.clgc.2025.102451_bib0029","doi-asserted-by":"crossref","first-page":"25.e21","DOI":"10.1016\/j.urolonc.2012.09.001","article-title":"Persistence of urothelial carcinoma of the bladder risk among former smokers: results from a contemporary, prospective cohort study","volume":"32","author":"Welty","year":"2014","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102451_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.juro.2015.02.081","article-title":"Lynch syndrome: a primer for urologists and panel recommendations","volume":"194","author":"Mork","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102451_bib0031","article-title":"The emerging landscape of germline variants in urothelial carcinoma: implications for genetic testing","volume":"23","author":"Vlachostergios","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"5","key":"10.1016\/j.clgc.2025.102451_bib0032","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.juro.2010.12.102","article-title":"Upper urinary tract carcinoma in Lynch syndrome cases","volume":"185","author":"Crockett","year":"2011","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.clgc.2025.102451_bib0033","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clgc.2025.102451_bib0034","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clgc.2025.102451_bib0035","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clgc.2025.102451_bib0036","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clgc.2025.102451_bib0037","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clgc.2025.102451_bib0038","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2025.102451_bib0039","article-title":"Significance of PD-L1 in metastatic urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"7","author":"Maiorano","year":"2024","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.clgc.2025.102451_bib0040","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.trecan.2023.07.002","article-title":"Tumor-agnostic drug development in dMMR\/MSI-H solid tumors","volume":"9","author":"Bhamidipati","year":"2023","journal-title":"Trends Cancer"},{"issue":"13","key":"10.1016\/j.clgc.2025.102451_bib0041","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.clgc.2025.102451_bib0042","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2025.102451_bib0043","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP Inhibitors in ovarian cancer: a review","volume":"18","author":"O\u2019Malley","year":"2023","journal-title":"Target Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102451_bib0044","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clgc.2025.102451_bib0045","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clgc.2025.102451_bib0046","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.clgc.2025.102451_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00264","article-title":"Clinical activity of olaparib in urothelial bladder cancer with DNA damage response gene mutations","author":"Sweis","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2025.102451_bib0048","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00095","article-title":"Phase II trial of olaparib in patients with metastatic urothelial cancer harboring DNA damage response gene alterations","author":"Doroshow","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2025.102451_bib0049","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2022.40.6_suppl.437","article-title":"BAYOU: a phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC)","volume":"40","author":"Rosenberg","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102451_bib0050","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12885-021-08085-z","article-title":"Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)","volume":"21","author":"Grivas","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2025.102451_bib0051","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13073-020-00744-3","article-title":"Ancestry-specific predisposing germline variants in cancer","volume":"12","author":"Oak","year":"2020","journal-title":"Genome Med"},{"issue":"5","key":"10.1016\/j.clgc.2025.102451_bib0052","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1200\/OP.22.00804","article-title":"Germline testing in prostate cancer: implementation and disparities of care","volume":"19","author":"Brown","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"10.1016\/j.clgc.2025.102451_bib0053","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41585-022-00580-7","article-title":"Germline testing and genetic counselling in prostate cancer","volume":"19","author":"Russo","year":"2022","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102451_bib0054","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN Guidelines insights: prostate cancer, version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.clgc.2025.102451_bib0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102451_bib0056","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732500151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732500151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T21:07:38Z","timestamp":1770671258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732500151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S155876732500151X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102451","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102451"}}